Cargando…

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients

Relevant meta-analyses have confirmed the cardiovascular and renal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) among patients with type 2 diabetes (T2D) and/or cardiorenal disease. However, it is not established whether the co...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Lixin, Qin, Jiao, Wang, Dengchuan, Zhao, Yunhui, Xu, Ning, Wu, Chaowen, Yuan, Jianpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676496/
https://www.ncbi.nlm.nih.gov/pubmed/36419835
http://dx.doi.org/10.3389/fphys.2022.1028486
_version_ 1784833609749757952
author Du, Lixin
Qin, Jiao
Wang, Dengchuan
Zhao, Yunhui
Xu, Ning
Wu, Chaowen
Yuan, Jianpeng
author_facet Du, Lixin
Qin, Jiao
Wang, Dengchuan
Zhao, Yunhui
Xu, Ning
Wu, Chaowen
Yuan, Jianpeng
author_sort Du, Lixin
collection PubMed
description Relevant meta-analyses have confirmed the cardiovascular and renal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) among patients with type 2 diabetes (T2D) and/or cardiorenal disease. However, it is not established whether the combination therapy of SGLT2i and GLP1RA will yield an additive benefit on cardiorenal endpoints. Lopez and colleagues recently did a cohort study (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93) and aimed to address this issue. However, their findings are not consistent with those of previous studies. To confirm Lopez et al.’s findings (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93) and address the aforementioned inconsistencies, we conducted a meta-analysis based on relevant studies. Our meta-analysis identified that SGLT2i + GLP1RA combination therapy was significantly associated with the reduced risks of cardiovascular/cerebrovascular atherosclerotic, heart failure-associated, and death outcomes compared with SGLT2i/GLP1RA monotherapy. These might support this combination therapy used for better reducing cardiovascular and death events in T2D patients, especially in those with high or very high cardiovascular risk. This is a commentary on a previous article (Lopez et al.’s study (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93)) published outside of Frontiers. Therefore, we submitted this manuscript as an Opinion article, as suggested in the Author Guidelines.
format Online
Article
Text
id pubmed-9676496
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96764962022-11-22 Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients Du, Lixin Qin, Jiao Wang, Dengchuan Zhao, Yunhui Xu, Ning Wu, Chaowen Yuan, Jianpeng Front Physiol Physiology Relevant meta-analyses have confirmed the cardiovascular and renal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) among patients with type 2 diabetes (T2D) and/or cardiorenal disease. However, it is not established whether the combination therapy of SGLT2i and GLP1RA will yield an additive benefit on cardiorenal endpoints. Lopez and colleagues recently did a cohort study (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93) and aimed to address this issue. However, their findings are not consistent with those of previous studies. To confirm Lopez et al.’s findings (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93) and address the aforementioned inconsistencies, we conducted a meta-analysis based on relevant studies. Our meta-analysis identified that SGLT2i + GLP1RA combination therapy was significantly associated with the reduced risks of cardiovascular/cerebrovascular atherosclerotic, heart failure-associated, and death outcomes compared with SGLT2i/GLP1RA monotherapy. These might support this combination therapy used for better reducing cardiovascular and death events in T2D patients, especially in those with high or very high cardiovascular risk. This is a commentary on a previous article (Lopez et al.’s study (Lopez et al., Am. J. Cardiol., 2022, 181, 87–93)) published outside of Frontiers. Therefore, we submitted this manuscript as an Opinion article, as suggested in the Author Guidelines. Frontiers Media S.A. 2022-11-07 /pmc/articles/PMC9676496/ /pubmed/36419835 http://dx.doi.org/10.3389/fphys.2022.1028486 Text en Copyright © 2022 Du, Qin, Wang, Zhao, Xu, Wu and Yuan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Du, Lixin
Qin, Jiao
Wang, Dengchuan
Zhao, Yunhui
Xu, Ning
Wu, Chaowen
Yuan, Jianpeng
Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
title Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
title_full Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
title_fullStr Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
title_full_unstemmed Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
title_short Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
title_sort meta-analysis assessing the effectiveness of sglt2i+glp1ra combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676496/
https://www.ncbi.nlm.nih.gov/pubmed/36419835
http://dx.doi.org/10.3389/fphys.2022.1028486
work_keys_str_mv AT dulixin metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients
AT qinjiao metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients
AT wangdengchuan metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients
AT zhaoyunhui metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients
AT xuning metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients
AT wuchaowen metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients
AT yuanjianpeng metaanalysisassessingtheeffectivenessofsglt2iglp1racombinationtherapyversusmonotherapyoncardiovascularandcerebrovascularoutcomesindiabeticpatients